🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT07134387
Recruiting Observational

Long-Term Burden of BPD and Health-Related Quality of Life (BronQ Family)

NCT07134387 · tracked via the Priya Life Science Germany tracker
Sponsor
Global Foundation for the Care of Newborn Infants
Phase
Observational
Started
2025-09-16
Last updated
2025-11-21

Condition(s) studied

Bronchopulmonary Dysplasia (BPD)Chronic Lung Disease of NewbornHRQOL (Health Related Quality Of Life)

Investigational drug(s) / intervention(s)

N/A, no intervention, participation in survey

N/A, no intervention, participation in survey: A unified questionnaire will be utilized for all participants, irrespective of their group assignment. Participants will be assigned to the BPD or comparison group retrospectively, based on their answers defining the BPD-status. To enhance comprehension, the questionnaire avoids using the term "BPD" wherever feasible and instead employs a more general reference to lung problems.

Study summary

The objective of this study is to examine the long-term impact of having a child with Bronchopulmonary Dysplasia (BPD) on the parents and caregivers from the time of diagnosis through adulthood. The primary focus will be on parents and caregivers of children until the age of 18 (\< 18) years who were diagnosed with BPD as newborns. Data will be collected through an online questionnaire in France, Germany, Italy, the Netherlands, Spain, the United Kingdom (including Northern Ireland), and the United States. It will ask about inclusion and exclusion criteria, background information (caregiver, child, and family situation), the child's medical situation, parental health-related quality of life (HRQoL), health literacy, feelings, support structures, and economic burden of the family.

Eligibility

Sex
ALL
Min age
0 Years
Max age
18 Years
Healthy volunteers
Accepted
Inclusion Criteria: BPD-group: * Being a parent or primary caregiver of a child until the age of 18 years (0 to under 18 years), * who was born preterm (before 37 weeks of gestation), * who has been discharged from their initial hospital stay after birth, * who suffered from BPD in the newborn period and * who was born or is currently living in the following countries: France, Germany, Italy, the Netherlands, Spain, the United Kingdom (including Northern Ireland) and the United States * providing sufficient proficiency in one of the languages of the questionnaire Control group: * Being a parent or primary caregiver of a child until the age of 18 years (0 to under 18 years), * who was born preterm (before 37 weeks of gestation), * who has been discharged from their initial hospital stay after birth, * who did not suffer from BPD in the newborn period and * who was born or is currently living in the following countries: France, Germany, Italy, the Netherlands, Spain, the United Kingdom (including Northern Ireland) and the United States * providing sufficient proficiency in one of the languages of the questionnaire Exclusion Criteria: BPD-group: * Other family members than parents/primary caregivers * Parents or primary caregivers * of a child older/equal than 18 years of age * of a child with BPD who has not been discharged yet * of a child without a BPD in the newborn period * with insufficient proficiency in one of the languages available in the questionnaire Control group: * Other family members than parents/primary caregivers * Parents or primary caregivers * of children older/equal than 18 years of age * of a child born term * of a child without BPD who has not been discharged yet * with insufficient proficiency in one of the languages available in the questionnaire

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Global Foundation for the Care of Newborn Infants (GFCNI) München Bavaria Recruiting

More Global Foundation for the Care of Newborn Infants trials in Germany

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07134387 on ClinicalTrials.gov ↗ ← All trials in Germany